The clinical significance of coagulation and the inflammatory response in autoimmunity

Clinical Reviews in Allergy and Immunology

Volumn 42, Issue 2, 2012, Pages 172-180

  Rubio Jurado, Benjamín ^a,c   Iñiguez Franco, Paulina ^a   Reyes, Pedro A ^b,d   Robles, Gustavo ^b   Salazar Páramo, Mario ^a,c   Zavala Cerna, Guadalupe ^c,e   Riebeling, Carlos ^a,d   Nava, Arnulfo ^a,c,d,e,f  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

^f HOSPITAL GENERAL DE OCCIDENTE   (Mexico)

Author keywords

Anticardiolipin; Antiphospholipid; Thrombophilia; Thrombosis

Indexed keywords

ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9A; CARDIOLIPIN ANTIBODY; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LOW DENSITY LIPOPROTEIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLASMIN; PROTEIN C; PROTEIN S; SELECTIN; THROMBIN;

ANTITHROMBIN III DEFICIENCY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD CLOTTING; CELL ACTIVATION; CELL ADHESION; CELL INTERACTION; COMPLEMENT SYSTEM; ENDOTHELIUM CELL; GENE MUTATION; HEMOSTASIS; HUMAN; HUMORAL IMMUNITY; HYPERCOAGULABILITY; INFLAMMATION; LEUKOCYTE; OXIDATION; PATHOGENESIS; PROTEIN DEFICIENCY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOPHILIA; THROMBOSIS; VASCULITIS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; BLOOD COAGULATION; BLOOD PLATELETS; FACTOR XIIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; THROMBIN; THROMBOSIS;

EID: 84862860465     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-010-8240-0     Document Type: Review

References (74)

1. Williamson D, Brown K, Luddington R, Baglin C, Baglin T (1998) Factor V Cambridge: a new mutation (Arg306-Thr) associated with resistance to activated protein C. Blood 91:1140-1144 (Pubitemid 28086865)
2. Gutiérrez-Tous MR (2005) Trombofilia, ¿cuándo, qué pruebas y a quién? Sem Fund Esp Reumatol 6:133-143 (Pubitemid 43120909)
3. De Stefano V, Rossi E, Paciaroni K, Leone G (2002) Screening for inherited thrombophilia: indications and therapeutic implica-tions. Haematologica 87:1095-1108 (Pubitemid 35192223)
4. Eichinger S (2005) Deep vein thrombosis. Lancet 365:1163-1174 (Pubitemid 40417567)
5. Hertzberg M (2005) Genetic testing for thrombophilia mutations. Sem Thromb Hemost 31:33-38 (Pubitemid 40262135)
6. Mannuccio MP (2001) Genetic hypercoagulability: prevention suggests testing family members. Blood 98:21-22
7. Rubio-Jurado B, Salazar Páramo M, Medrano Muñoz F, González-Ojeda A, Nava A (2007) Trombofilia, Autoinmunidad Y Trombo-profilaxis Postoperatoria. CirCiruj 75:313-323
8. Dahlbäck B (2005) Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 257:209-223 (Pubitemid 40342124)
9. Bombeli T, Spahn DR (2004) Updates in perioperative coagulation: physiology and management ofthromboembolism and haemorrhage. Br J Anaesth 93:275-287 (Pubitemid 39117404)
10. Carrillo ER, Salmeron NP, Carvajal RR, Contreras DV, Hernández AC (2004) Rompiendo un paradigma: del modelo humoral al modelo celular de la coagulación. Su aplicación clínica en el enfermo grave. Med Crit Ter Int XVIIII(1):17-23
11. Mackman N (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24:1015-1022
12. Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8 (11):1227-1234 (Pubitemid 35373553)
13. Orfeo T, Butenas S, Brummel-Ziedins KE, Man K (2005) The tissue factor requirement in blood coagulation. J Biol Chem 280:42887-42896 (Pubitemid 43049251)
14. De Groot PG, Derksen RH (2004) Pathophysiology ofantiphos-pholipid antibodies. Neth J Med 62(8):267-272
15. Bas de Laat H, Derksen RH, Urbanus RT, Roest M, de Groot PG (2004) ß2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104:3598-3602 (Pubitemid 39564433)
16. Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y (2006) The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematous. Hematologica 91:699-702 (Pubitemid 43799474)
17. Ortel Thomas L (2006) The syndrome antiphospholipid: what are we really measuring? How do we measure it? And how do we treat it? J Thromb Thrombolysis 21:79-83
18. Salobir B, Sabovic M, Hojnikc M, Cucnikc S, Kveder T (2007) Anti-b2-glycoprotein I antibodies of IgM class are linked to thrombotic disorders in young women without autoimmune disease. Immunobiology 212:193-199 (Pubitemid 46505957)
19. Giannakopoulos B, Passam F, Rahgoza SA, Krilis S (2007) Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109:422-430 (Pubitemid 46105935)
20. Urbanus RT, Derksen R, de Groot PG (2008) Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Rev 22:93-105 (Pubitemid 351282442)
21. de Groot PG, Derksen RH (2007) Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 3:1854-1860 (Pubitemid 41716572)
22. Pierangeli S, Chen PP, González EB (2006) Antiphospholipid antibodies and the antiphospholipid syndrome:an update on treatment and pathogenic mechanisms. Curr Opin Hematol 13:366-375 (Pubitemid 44168459)
23. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MA, Palomo I, Harris N, Meroni PL (2008) Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 34:236-250
24. De Laat B, Mertens K, de Groot PG (2008) Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nature clinical practice. Rheumatology 4 (4):192-199
25. Oku K, Atsumi T, Amengual O, Koike T(2008) Antiprothrombin antibody testing: detection and clinical utility. Semin Thromb Hemost 34:335-339
26. Ishikura K, Wada H, Kamikura Y, Hattori K, Fukuzawa T, Yamada N, Nakamura M, Nobori T, Nakano T (2004) High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. Am J Hematol 76:338-342 (Pubitemid 38988617)
27. Bertolaccini M, Gomez S, Pareja JF, Theodoridou A, Sanna G, Hughes GRV, Khamashta MA (2005) Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 64:1639-1643 (Pubitemid 41532050)
28. Amengual O, Atsumi T, Koike T (2003) Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 48(4):886-895 (Pubitemid 36418230)
29. Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115:3378-3384 (Pubitemid 43121822)
30. Langer HF, Chavakis T (2009) Leukocyte-endothelial interactions in inflammation. J Cell Mol Med 13(7):1211-1220, Epub 2009 Jun 16. Review. PubMed PMID:19538472; PubMed Central PMCID: PMC2861890)
31. Vestweber D (1992) Selectins: cell surface lectins which mediate the binding of leukocytes to endothelial cells. Semin Cell Biol 3 (3):211-220, Review. PubMed PMID: 1623209
32. Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69(1):11-25, Review. PubMed PMID: 1555235
33. Chavakis T, Kanse SM, May AE, Preissner KT (2002) Haemo-static factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation. Biochem Soc Trans 30(2):168-173, Review. PubMed PMID: 12023845
34. Springer TA (1995) Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 57:827-872, Review. PubMed PMID:7778885
35. Orlova VV, Chavakis T (2007) Regulation ofvascular endothelial permeability by junctional adhesion molecules (JAM). Thromb Haemost 98(2):327-332, PubMed PMID: 17721614)
36. Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, Lambris JD, Huber-Lang M (2008) Interaction between the coagulation and complement system. Adv Exp Med Biol 632:71-79, Review. PubMed PMID: 19025115; PubMed Central PMCID:PMC2713875
37. Hierholzer C, Billiar TR (2001) Molecular mechanisms in the early phase of hemorrhagic shock. Langenbecks Arch Surg 386 (4):302-308, Review. PubMedPMID: 11466573 (Pubitemid 32702760)
38. Davis AE 3rd (2004) Biological effects of C1 inhibitor. Drug News Perspect 17(7):439-446, Review. PubMed PMID: 15514703
39. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12(6):682-687, Epub 2006 May 21. PubMedPMID: 16715088 (Pubitemid 43865238)
40. von Hundelshausen P, Weber C (2007) Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100:27-40 (Pubitemid 46066771)
41. Mackman N (2008) Triggers, targets and treatments for thrombo-sis. Nature 451(21):914-918
42. Levi M, Nieuwdorp M, van der Poll T, Stroes E (2008) Metabolic modulation of inflammation-induced activation of coagulation. Sem Thromb Hemost 43(1):26-32 (Pubitemid 351640879)
43. Liuzzo G, Giubilato G, Pinnelli M(2005)T cells and cytokines in atherogenesis. Lupus 14:732-735 (Pubitemid 41413301)
44. Frostegård J (2005) Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 25:1776-1785 (Pubitemid 41243443)
45. Hansson GK, Libby P (2006) The immune response in athero-sclerosis: a double-edged sword. Nat Rev Immunol 6:508-519 (Pubitemid 43980523)
46. Lopez LR, Simpson DF, Hurley BL, Matsuura E (2005) OxLDL/ beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann NY Acad Sci 1051:313-322, PubMed PMID: 16126973 (Pubitemid 41362761)
47. Lopez LR, Salazar-Paramo M, Palafox-Sanchez C, Hurley BL, Matsuura E, Garcia-De La Torre I (2006) Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thick-ness: implications in autoimmune-mediated atherosclerosis. Lupus 15(2):80-86, PubMed PMID: 16539278 (Pubitemid 43345332)
48. McMahon M, Hahn BH (2007) Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 19(6):633-639, Review. PubMed PMID: 18083018; PubMed Central PMCID: PMC2709458
49. Zampieri S, Iaccarino L, Ghirardello A, Tarricone E, Arienti S, Sarzi-Puttini P, Gambari P, Doria A (2005) Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann NY Acad Sci 1051:351-361, Review. PubMed PMID: 16126977 (Pubitemid 41362765)
50. Greco TP, Conti-Kelly AM, Greco T Jr, Doyle R, Matsuura E, Anthony JR, Lopez LR (2009) Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol 132(4):613-620, PubMed PMID: 19762540
51. Greco TP, Conti-Kelly AM, Anthony JR, Greco T Jr, Doyle R, Boisen M, Kojima K, Matsuura E, Lopez LR (2010) Oxidized-LDL/beta(2)-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes. Am J Clin Pathol 133(5):737-743, PubMed PMID: 20395520
52. Dalen JE (2008) Should patients with venous thromboembolism be screened for thrombophilia? Am J Med 121(6):458-463
53. Perry DJ (1994) Antithrombin and its inherited deficiencies. Blood Rev 8(1):37-55
54. Rosendaal FR, Koster T, Vandenbrouke JP, Reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504-1508
55. Majluf-Cruz A (2003) La realidad de la prevalencia de la trombosis. Gac Méd Méx 139(S2):66-68
56. Ruiz-Arguelles GJ, Poblete-Naredo I, Reyes-Nuñez V, Garcés-Eisele J, Lopez Martinez B, Gómez-Rangel JD (2004) Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients. Rev Invest Clin 56:600-604
57. Tripodi A (2003) Levels of coagulation factors and venous thromboembolism. Hematologica 88:705-711 (Pubitemid 36781599)
58. Mangiafico R, Sarnataro F, Mangiafico M, Fiore CE (2006) Impaired cognitive performance in asymptomatic peripheral arterial disease: relation to C-reactive protein and D-dimer levels. Age Ageing 35:60-65 (Pubitemid 43124923)
59. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and risks ofcardiovascular disease in apparently healthy men. N Engl J Med 336:973-979 (Pubitemid 27152782)
60. Sepulveda JL, Mehta JL (2005) C-reactive protein and cardiovas-cular disease: a critical appraisal. Curr Opin Cardiol 20(5):407-416 (Pubitemid 41192158)
61. Tohgi H, Konno S, Takahashi S, Koizumi D, Kondo R, Takahashi H (2000) Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thromb Res 100:373-379 (Pubitemid 32056968)
62. Di Napoli M, Papa F (2002) Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 33:1763-1771 (Pubitemid 34761057)
63. Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa D, Kurosawa S (1999) Inflammation, sepsis, and coagulation. Haematologica 84:254-259 (Pubitemid 29476931)
64. Crocea K, Libby P (2007) Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 14:55-61 (Pubitemid 44885613)
65. Johnson CM, Mureebe L, Silver D (2005) Hypercoagulable states: a review. Vasc Endovasc Surg 39:123-133 (Pubitemid 40489847)
66. Samama MM, Dahl O, Mismetti P et al (2006) An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica 91:64-70 (Pubitemid 43235387)
67. Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome. JAMA 295:1050-1057
68. Crowther MA et al (2003) A comparasion of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Eng J Med 349:1133-1138 (Pubitemid 37122325)
69. Salmon JE, Girardi G, Lockshin MD (2007) The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol 3 (3):140-147 (Pubitemid 46416262)
70. Danese S, Dejana E, Fiocchi C (2007) Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol 178 (10):6017-6022, Review. PubMed PMID: 17475823 (Pubitemid 46717378)
71. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM (1998) Endothelial cells in physiology and in the pathophysiology of vasculardisorders. Blood91(10):3527-3561, Review. PubMed PMID: 9572988 (Pubitemid 28225719)
72. Wolinsky H (1980) A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understand-ing atherogenesis. Circ Res 47(3):301-311, Review. PubMed PMID: 6996862 (Pubitemid 10001078)
73. Tofler GH, Massaro J, Levy D, Mittleman M, Sutherland P, Lipinska I, Muller JE, D'Agostino RB (2005) Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am J Cardiol 96:1280-11283
74. Xu J, Lupu F, Esmon CT (2010) Inflammation, innate immunity and blood coagulation. Hamostaseologie 30(1):5-9